Global Immuno-Oncology Cell Therapy Market

Report ID : 1083 | Published : 2021-07-23 | Pages: 140 | Format: PDF/EXCEL

Immuno-oncology cell therapies are a remarkably promising treatment for a different types of cancer patients. The approval of CAR-T cell therapy products represents one of the most significant breakthroughs in cancer since the introduction of chemotherapy. Immuno-oncology cell therapies are one of the fastest advancing technology along with huge research and development activities. The oncology market today could be quickly superseded by next generation therapies in the upcoming forecast period. The Immuno-oncology Cell Therapy market is driven by factors such as increasing research funding in the immune-oncology, rising prevalence of cancer and focus on research activities from government health institutions and pharma giants inImmuno-oncology therapy development.


The global immuno-oncology cell therapies market is classified based on therapy type and region. Based on the therapy type, the market is segmented into CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, and Other Cell Therapies.
Geographically, the Americas dominate the immuno-oncology cell therapies market owing to high healthcare expenditure and the rise in awareness among people. Europe stands for the second position in the immuno-oncology cell therapies market. It is expected that the support provided by government bodies for research & development and increased clinical trial programs in healthcare is going to drive the market in the Europe region. The Asia Pacific is known to be the fastest-growing immuno-oncology cell therapies market leading to a huge patient pool, developing healthcare technology and improving healthcare expenditure. The Middle East & Africa has the lowest market for immuno-oncology cell therapies due to inadequate medical facilities and lack of technical knowledge.
Some of key the players involved in the clinical trials/R&D activities Immuno-oncology cell therapies market are Novartis, Juno Therapeutics, Agios Pharmaceutical, Atara Biotherapeutics, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio, Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, Editas Medicine, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm, JW Therapeutics, Medigene, MedisixTherapeutics, Lion TCR, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, Posedia Therapeutics, Zelluna Immunotherapy, and others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Immuno-oncology Cell Therapy Market Snapshot

Chapter 4. Global Immuno-oncology Cell Therapy Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis of Key Immuno-oncology Cell Therapy Industry

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Clinical Trial/Pipeline Analysis 2020

4.8. COVID-19 Impact on Oncology Industry

Chapter 5. Market Segmentation 1: Therapy Type Estimates & Trend Analysis

5.1. Therapy Type & Market Share, 2020 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Therapy Type:

5.2.1. CAR-T Cells

5.2.2. NK & NKT Cells

5.2.3. TCR T Cells

5.2.4. TAA/TSA targeted T Cell

5.2.5. Cytokine-induced killer cells

5.2.6. Dendritic cells

5.2.7. Macrophages

5.2.8. Other Cell Therapies

Chapter 6. Market Segmentation 2: Indication Type Estimates & Trend Analysis

6.1. Indication Type & Market Share, 2020 & 2028

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Indication Type:

6.2.1. Head & Neck Cancer

6.2.2. Lung Cancer

6.2.3. Kidney Cancer

6.2.4. Melanoma

6.2.5. Lymphoma

6.2.6. Leukemia

6.2.7. Others

Chapter 7. Immuno-oncology Cell Therapy Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Therapy Type, 2020-2028

7.1.2. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2020-2028

7.1.3. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2020-2028

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2020-2028

7.2.2. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2020-2028

7.2.3. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2020-2028

7.2.3.1. Germany

7.2.3.2. Poland

7.2.3.3. France

7.2.3.4. Italy

7.2.3.5. Spain

7.2.3.6. UK

7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2020-2028

7.3.2. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2020-2028

7.3.3. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2020-2028

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2020-2028

7.4.2. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2020-2028

7.4.3. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2020-2028

7.4.3.1. Brazil

7.4.3.2. Rest of Latin America

7.5. Middle East & Africa

7.5.1. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, (US$ Million)

7.5.2. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2020-2028

7.5.3. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2020-2028

7.5.3.1. South Africa

7.5.3.2. GCC Countries

7.5.3.3. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Novartis

8.2.2. Juno Therapeutics

8.2.3. Agios Pharmaceutical

8.2.4. Adicet Bio, Inc.

8.2.5. Adaptimmune Therapeutics plc.

8.2.6. Atara Biotherapeutics

8.2.7. Artiva Biotherapeutics, Inc.

8.2.8. Shenzhen BinDeBio Ltd.

8.2.9. Editas Medicine

8.2.10. China Immunotech Co., Ltd.

8.2.11. CRISPR Therapeutics

8.2.12. Lion TCR

8.2.13. Autolus Limited

8.2.14. Kite Pharma

8.2.15. Bellicum Pharmaceuticals

8.2.16. bluebird bio

8.2.17. Calibr

8.2.18. Carina Biotech

8.2.19. CARsgen Therapeutics

8.2.20. Celgene Corporation

8.2.21. Cellectis

8.2.22. Cell Medica

8.2.23. Allogene Therapeutics

8.2.24. Amgen

8.2.25. Cell Design Labs

8.2.26. Celularity

8.2.27. Celyad

8.2.28. Eureka Therapeutics

8.2.29. Fate Therapeutics

8.2.30. Fortress Bio

8.2.31. Gilead Sciences

8.2.32. Immatics US Inc.

8.2.33. Immunocore

8.2.34. Sorrento Therapeutics, Inc.

8.2.35. Janssen Biotech

8.2.36. JW Therapeutics

8.2.37. Kleo Pharmaceuticals

8.2.38. Medisix Therapeutics

8.2.39. Mustang Bio

8.2.40. Medigene

8.2.41. NantKwest

8.2.42. Nanjing Legend Biotech

8.2.43. Precision Biosciences

8.2.44. Posedia Therapeutics

8.2.45. T-Cure Biosciences Inc

8.2.46. TCR2 Therapeutics

8.2.47. T-knife

8.2.48. TScan Therapeutics

8.2.49. Triumvira Immunologics USA, Inc.

8.2.50. Ziopharm

8.2.51. Zelluna Immunotherapy

8.2.52. 3T Biosciences, Inc.

8.2.53. Other Prominent Players

Global Immuno-oncology Cell Therapy Market Segmentation

Global Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Therapy Type

  • CAR-T Cells
  • NK & NKT Cells
  • TAA/TSA targeted T Cell
  • TCR T Cell
  • Cytokine-induced killer cells
  • Dendritic cells
  • Macrophages
  • Other Cell Therapies

Global Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Major Indication

  • Head & Neck Cancer
  • Lung Cancer
  • Kidney Cancer
  • Melanoma
  • Lymphoma
  • Leukemia
  • others

Global Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Region

  • North America
  • Asia-Pacific
  • Europe
  • Latin America
  • Middle-East& Africa

Europe Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Country

  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Country

  • S.
  • Canada

Asia Pacific Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Immuno-oncology Cell Therapy Market Outlook 2019-2030 by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients